Publications

Detailed Information

Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line

DC Field Value Language
dc.contributor.authorShim, Seon-Hui-
dc.contributor.authorHah, J. Hun-
dc.contributor.authorHwang, So-Yeon-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorSung, Myung-Whun-
dc.date.accessioned2012-07-04T08:18:21Z-
dc.date.available2012-07-04T08:18:21Z-
dc.date.issued2010-04-
dc.identifier.citationONCOLOGY REPORTS; Vol.23 4; 1139-1143ko_KR
dc.identifier.issn1021-335X-
dc.identifier.urihttps://hdl.handle.net/10371/78479-
dc.description.abstractGlucocorticoids (GCs) modulate the synthesis of many pro-inflammatory cytokines and influence multiple transduction pathways. GCs negatively or positively influence the transcription factors of their target genes. All of these transcription signals are closely connected to cancer survival or death. We investigated the action of dexamethasone (DEX) on head and neck cancer cell lines. When SNU-1041 and SNU-1076 were treated with DEX, the cell lines showed different patterns of responses. DEX inhibition of cell growth depended on concentration in SNU-1041, but not in SNU-1076. Furthermore, DEX Suppressed Vascular endothelial growth factor (VEGF) secretion from SNU-1041, but not from SNU-1076. We explored the mechanism that explains these distinct differences. After DEX treatment, the differences of NF-kappa B (p65), glucocorticoid receptor and p-AKT were not observed between the cell lines. However, phospho-signal transducer and activator of transcription 3 (STAT3) decreased in SNU-1041 only. Moreover, STAT3 inhibition using si-RNA Suppressed VEGF secretion. When STAT3 was overexpressed after DEX treatment, the level of VEGF in the culture media was restored. Taken together, we suggest that p-STAT3 can be a mediating factor which regulates VEGF secretion in the DEX treatment. Because the relationship between the three Molecules DEX, STAT3 and VEGF is scarcely known, our findings clarified one of the signaling pathways of DEX, which is often used in clinical conditions.ko_KR
dc.language.isoenko_KR
dc.publisherSPANDIDOS PUBL LTDko_KR
dc.subjectdexamethasoneko_KR
dc.subjectsignal transducer and activator of transcription 3ko_KR
dc.subjecthead and neck squamous cell carcinomako_KR
dc.subjectvascular endothelial growth factorko_KR
dc.titleDexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell lineko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor심선휘-
dc.contributor.AlternativeAuthor황소연-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor성명훈-
dc.identifier.doi10.3892/or_00000743-
dc.citation.journaltitleONCOLOGY REPORTS-
dc.description.citedreferenceShim SH, 2009, INT J MOL MED, V23, P805, DOI 10.3892/ijmm_00000196-
dc.description.citedreferenceMatthews L, 2009, ENDOCRINOLOGY, V150, P75, DOI 10.1210/en.2008-0196-
dc.description.citedreferenceWilson C, 2008, BRIT J CANCER, V99, P2054, DOI 10.1038/sj.bjc.6604804-
dc.description.citedreferenceEgberts JH, 2008, CANCER BIOL THER, V7, P1044-
dc.description.citedreferenceChen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101-
dc.description.citedreferenceSommer P, 2007, ONCOGENE, V26, P7111, DOI 10.1038/sj.onc.1210524-
dc.description.citedreferenceYemelyanov A, 2007, ONCOGENE, V26, P1885, DOI 10.1038/sj.onc.1209991-
dc.description.citedreferenceYano A, 2006, CLIN CANCER RES, V12, P3003, DOI 10.1158/1078-0432.CCR-05-2085-
dc.description.citedreferenceXie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674-
dc.description.citedreferenceXu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719-
dc.description.citedreferenceJung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje-
dc.description.citedreferenceSchmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456-
dc.description.citedreferenceYu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275-
dc.description.citedreferenceNECELA BM, 2004, P AM THORAC SOC, V1, P239-
dc.description.citedreferenceWang Z, 2003, J BIOL CHEM, V278, P50897, DOI 10.1074/jbc.M310297200-
dc.description.citedreferenceHerr I, 2003, CANCER RES, V63, P3112-
dc.description.citedreferenceNiu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj/onc/1205260-
dc.description.citedreferencePlaney SL, 2000, BIOCHEM BIOPH RES CO, V279, P307-
dc.description.citedreferenceKofler R, 2000, HISTOCHEM CELL BIOL, V114, P1-
dc.description.citedreferenceEvans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854-
dc.description.citedreferenceFOLKMAN J, 1995, NAT MED, V1, P27-
dc.description.citedreferenceFIDLER IJ, 1994, CELL, V79, P185-
dc.description.citedreferenceSANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215-
dc.description.citedreferenceBURNSTEIN KL, 1991, STEROIDS, V56, P52-
dc.description.citedreferenceHARMON JM, 1979, J CELL PHYSIOL, V98, P267-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share